A set of doctors' perspectives on what clinicians see as emerging device technologies in cardiology, orthopedics, and neurology. This article is excerpted from Windhover Information's annual START-UP Forum, held this year in the beginning of April in Boston, titled "Bringing Follow-on Funding to Heatlh Care."
By David Cassak and Stephen Levin
Windhover Information's annual START-UP Forum, held this year in the beginning of April in Boston, was titled "Bringing Follow-on Funding...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The companies announced positive Phase II results for AlphaMedix, a lead 212-based alpha emitter therapy for gastroenteropancreatic neuroendocrine tumors.
The company has presented the full set of positive results from the Phase IIb ANTHEM-UC trial in the inflammatory bowel disease.
The non-hormonal drug could be a big step forward in treating pain associated with the condition, but the Chinese company may still need a partner for its Phase III studies and eventual commercialization.
Japan's latest Nobel Prize win sparks hopes for renewed investment in biopharma R&D by the national government, including in a venture co-founded by the winner.
The companies announced positive Phase II results for AlphaMedix, a lead 212-based alpha emitter therapy for gastroenteropancreatic neuroendocrine tumors.
The company has presented the full set of positive results from the Phase IIb ANTHEM-UC trial in the inflammatory bowel disease.
The non-hormonal drug could be a big step forward in treating pain associated with the condition, but the Chinese company may still need a partner for its Phase III studies and eventual commercialization.
